Skip to main content
aTYR PHARMA INC logo

aTYR PHARMA INC — Investor Relations & Filings

Ticker · ATYR ISIN · US0021202025 LEI · 529900ENQUXMC5EBKO36 US Manufacturing
Filings indexed 709 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US ATYR

About aTYR PHARMA INC

https://www.atyrpharma.com/

aTyr Pharma is a clinical-stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. The company focuses on translating transfer RNA (tRNA) synthetase biology into potential first-in-class therapies. Its primary therapeutic areas of interest are fibrosis and inflammation. aTyr Pharma's lead clinical candidate, efzofitimod (ATYR1923), is being developed for the treatment of pulmonary sarcoidosis and other interstitial lung diseases. The company utilizes its proprietary platform to research the extracellular functionality and signaling pathways of tRNA synthetases to create new product candidates.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-15 English
8-K
Regulatory Filings
2026-05-15 English
8-K - aTYR PHARMA INC (0001339970) (Filer)
Regulatory Filings
2026-05-11 English
DEFA14A - aTYR PHARMA INC (0001339970) (Filer)
Regulatory Filings
2026-03-26 English
SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)
Major Shareholding Notification
2026-03-26 English
4 Filing
Director's Dealing
2026-02-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.